Point mutations in the AR gene are rarely detectable in early-stage PCa but are detected in 15–20% of CRPC patients and up to 40% of CRPC patients treated with AR antagonists, most frequently in the LBD, followed by the NTD [66,69]. Here, AR is linked to posterior cortical atrophy.